Search results

1

Aptamers RNA as potential antiviral drugs

100%

Tyczewska A., Figlerowicz M., Twardowski T.

|

issue 2

153-164

EN

SELEX is a method of the identification of high affinity aptamers for a surprising variety of molecular targets including nucleic acid binding proteins, non-nucleic acid binding proteins as well as small organic molecules. The aptamers against enzymes involved in infectious, malignant diseases are still being discovered by the process of SELEX. This procedure might be a way of finding new drugs that specifically and effectively block viral replication, e.g. HIV.

2

Pharmaceutical biotechnology: The achievements of Century XX and the expectations in Century XXI

80%

Chmiel A.

Biotechnologia

|

2002

|

issue 4

56-78

EN

Pharmaceutical biotechnology is 60 years old. Its development one can divide into three essential periods. Two of them have proceeded in past century. The first period started during the Second Warld War with the industrial production of penicillin and was microbiology-based (microbial metabolites as drugs). The second one was genetic engineering-based and started in 1982, when human insulin synthesized in recombinant bacteria was introduced by pharmaceutical industry to health care. The third period began in 2001 with the first descriptions of the human genome, and is genome-based (also proteome-based). Molecular biology with its new areas genomics, farmacogenomics and proteomics, together with bioinformatics and other sophfisticated tools developed at the end of XX century and introduced (the pharmaceutical and medical biotechnology of the XXI century) very new ideas and new approaches to drug discovery and designin. Pharmaceutical biotechnology (as well as pharmaceutical industry as a whole and world biotechnology as a whole) is entering upon the third phase of its development, a very integrated and globalized one.

3

Drug addiction as drive satisfaction (?antidrive?) dysfunction

80%

Kostkowski W.

Acta Neurobiologiae Experimentalis

|

2002

|

vol. 62

|

issue 2

111-117

EN

Drug addiction is a complex brain disorder, characterized by the loss of control over drug seeking and drug taking behavior, and by the risk of relapse, even after a prolonged period of abstinence. This disorder may have its source in a disturbed balance of drive-related behaviors, which control appetitive reactions aimed at seeking contact with an addictive substance. The act of consumption becomes more and more attractive, and the behavior takes on compulsive character. We suppose that drug addiction may involve a change in the mechanism of satisfaction of drives and states of satiation as well. To understand how the motivational processes are changed with the development of dependence, one must consider the mechanism of drive satisfaction and satiation states that occur in relation to the consumatory reflex. When a given drive is satisfied a state of fulfilment occurs. This state may be a result of a so-called ?antidrive? mechanism (Konorski 1967). While a drive activity is characterized by general activation and tension, the drive satisfaction state (?antidrive?) is characterized by relaxation and relief. When a particular drive is satisfied, the operation of other drives become possible. Therefore, we postulate that dysfunction of drive satisfaction leads to the sustained activation related to the current drug-related drive, which blocks the operation of other drives. In effect, uncontrolled compulsive appetitive behavior is released, and the operation of other drives is restrained, thus forcing the organism to focus on drug-related drive. The reason for an ?antidrive? dysfunction may be related to adaptive changes which develop during a contact with an addictive substance.

4

Antibodies and drug-carriers in targeted therapy - progress and limitations

80%

Konieczny L., Piekarska P. B., Piekarska B., Roterman R. I., Roterman I., Rybarska R. J., Rybarska J., Stopa S. B., Stopa B., Zemanek Z. G., Zemanek G.

|

EN

The paper addresses the problems of carriers and antibodies in targeted therapy. Also the new material of liquid crystalline nature, designed for use as a drug vehicle in the immune targeting technique is presented and its property is discussed. Obtained by self-assembling, the ribbon-like supramolecular organisation products of some azo-dyes, particularly including Congo red and Evans blue, form micellar bodies of this carrier. They bind spontaneously and selectively to immune complexes but not to free antibodies. The binding strongly enhances the antigen - antibody interaction. Micelles of the carrier composed of self-assembled molecules easily incorporate many foreign substances including drugs, favouring however those of possibly planar molecules. The excess of carrier leaves the organism rapidly through the urine tract, reducing the possible side effects. The nature of chromonic liquid crystalline material is suitable for many modifications and adapting elaboration.

5

Animals as bioreactors ? the future of pharmaceutical industry?

80%

Tyczewska A., Bakowska-Zywicka K.

Biotechnologia

|

2008

|

issue 3

64-70

EN

Biotechnology products and its application raise many controversies. Discussions are carried out where the supporters of GMO are underlining the qualities of genetically modified organisms, and sceptics are pointing the dangers that, in their perspective, are exceeding the benefits. In this article, we intend to show the qualities resulting from the use of transgenic animals to produce cheaper drugs, as biotechnology and genetic engineering methods gave the possibility to use animals as bioreactors.

6

Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system

70%

Hauff K., Zamzow C., Law W. J., De_Melo J., Kennedy K., Los M.

Archivum Immunologiae et Therapiae Experimentalis

|

2005

|

vol. 53

|

issue 4

308-320

EN

In this review we focus on peptide- and peptidomimetic-based approaches that target autoimmune diseases and some pathologies of the central nervous system. Special attention is given to asthma, allergic rhinitis, osteoarthritis, and Alzheimer's disease, but other related pathologies are also reviewed, although to a lesser degree. Among others, drugs like Diacerhein and its active form Rhein, Pralnacasan, Anakinra (Kineret), Omalizumab, an anti-beta chain antibody 'BION-1', are described below as well as attempts to target beta-amyloid peptide aggregation. Parts of the review are also dedicated to targeting of pathologic conditions in the brain and in other tissues with peptides as well as methods to deliver larger molecules through the 'blood-brain barrier' by exploring receptor-mediated transport, or elsewhere in the body by using peptides as carriers through cellular membranes. In addition to highlighting current developments in the field, we also propose, for future drug targets, the components of the inflammasome protein complex, which is believed to initiate the activation of caspase-1 dependent signaling events, as well as other pathways that signal inflammation. Thus we discuss the possibility of targeting inflammasome components for negative or positive modulation of an inflammatory response.

7

Biopharmaceuticals- a basic tool of modern pharmacotherapy

61%

Kaliszan R., Dlugokecka J.

Biotechnologia

|

2009

|

issue 5

33-49

EN

Current status of innovative drug industry is briefly presented with emphasis on new biopharmaceuticals introduced in the years 1995-2007. Adverse effects and problems of safety and effectiveness of these pharmacotherapeutics are reviewed. A separate part of the manuscript is devoted to the newly introduced methods of molecular diagnostics based on pharmacogenomics and employed in personalized medicine. Theranostic approach consisting in a joint use of drugs and companion diagnostics are characterized.

Refine search results

Aptamers RNA as potential antiviral drugs

Pharmaceutical biotechnology: The achievements of Century XX and the expectations in Century XXI

Drug addiction as drive satisfaction (?antidrive?) dysfunction

Antibodies and drug-carriers in targeted therapy - progress and limitations

Animals as bioreactors ? the future of pharmaceutical industry?

Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system

Biopharmaceuticals- a basic tool of modern pharmacotherapy